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Abstract
The b-adrenoceptors (b-ARs) control many cellular processes. Here, we show that b-ARs inhibit calcium depletion-induced
cell contractility and subsequent cell detachment of L6 skeletal muscle cells. The mechanism underlying the cell detachment
inhibition was studied by using a quantitative cell detachment assay. We demonstrate that cell detachment induced by
depletion of extracellular calcium is due to myosin- and ROCK-dependent contractility. The b-AR inhibition of L6 skeletal
muscle cell detachment was shown to be mediated by the b2-AR and increased cAMP but was surprisingly not dependent
on the classical downstream effectors PKA or Epac, nor was it dependent on PKG, PI3K or PKC. However, inhibition of
potassium channels blocks the b2-AR mediated effects. Furthermore, activation of potassium channels fully mimicked the
results of b2-AR activation. In conclusion, we present a novel finding that b2-AR signaling inhibits contractility and thus cell
detachment in L6 skeletal muscle cells by a cAMP and potassium channel dependent mechanism.
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Introduction
Adrenoceptors (ARs) are G protein coupled receptors (GPCRs)
expressed in virtually all organs in the body. They can be activated
by the hormone epinephrine and the neurotransmitter norepi-
nephrine and signal to several endpoints in different tissues. There
are three pharmacologically distinct subtypes of ARs: a1-, a2- and
b-ARs. The b-adrenoceptors (b-ARs) are currently classified into
b1-, b2- and b3-ARs which are predominantly Gs-protein-coupled
receptors. The classical mechanism for signal transduction
downstream of b-ARs is activation of adenylate cyclase (AC)
which catalyzes the conversion of adenosine triphospate (ATP) to
cyclic 39,59 adenosine monophosphate (cAMP). One of the major
downstream effectors of cAMP is the serine/threonine protein
kinase A (PKA). Upon increased levels in the cell, cAMP binds to
the regulatory subunit of PKA which results in the dissociation and
consequent activation of the catalytic subunit, which subsequently
targets several proteins. It is also well documented that cAMP can
act via the exchange factor directly activated by cAMP (Epac)
[1,2], a guanine nucleotide-exchange factor (GEF) that can
activate Rap1, a small Ras-like GTPase involved in cellular
functions such as cell proliferation, differentiation, apoptosis and
adhesion. A third, less well-studied, target of cAMP includes ion
channels that can be directly activated by cAMP binding.
Nucleotide binding and activation of channels has been charac-
terized in two protein families: the cyclic nucleotide-gated
channels (CNG) and the hyperpolarization-activated cyclic
nucleotide-gated (HCN) channels. Modulation of ion-transport
by cAMP has also been proposed to occur with other Na
+- and
K
+-channels [3,4].
Addtionally, stimulation of b-ARs can also induce cAMP-
independent signals. The most well described of these is the b-
arrestin pathway, though bc-dependent events have also been
suggested.
Thus, the b-adrenoceptor is capable of activating multiple
signaling cascades, leading to several cellular and physiological
endpoints. In skeletal muscle systems, several b-adrenergic effects
have been described: increased protein synthesis and reduced
protein degradation, both of which lead to increased muscle mass;
potentiation of muscle twitch; enhanced activity of ion channels,
increased lipolysis via hormone sensitive lipase (HSL); enhanced
glycogen metabolism, and; increased glucose uptake. The latter
endpoint has been the subject of several studies and seems to be
regulated by the b2-AR via both cAMP-dependent and indepen-
dent pathways. In the L6 cell line, a commonly used model system
for skeletal muscles, b-adrenergic stimulation induces glucose
uptake though multiple signaling pathways [5], in which, glucose
uptake is only partly blocked by cAMP-inhibition [5], suggesting
the involvement of atypical signaling.
In the current paper we present evidence that the b-adrenergic
pathway affects cell morphology and contractility. In the following
text we have defined contractility as the ability of cells to contract/
becoming shorter, both regarding muscle and non-muscle cells.
We primarly investigated the effect of b-AR signaling on
contractility in skeletal muscle, using the L6 cell line. For this,
we employed an assay in which the cells were treated with the
calcium chelator EDTA or calcium-free PBS. Removal of
extracellular Ca
2+ has been used in several studies as a model
system for cellular contraction [6–10]. Though the mechanism is
not fully elucidated, it is shown to be myosin II dependent [11]
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+
permeability [12]. It has also been shown that channels that
normally transport Ca
2+ can, in the absent of Ca
2+ ions, transport
Na
+ across the plasma membrane [13]. In Caco-2 intestinal
epithelial cells, openings in tight-junctions upon treatment with
calcium-free buffer was proposed to be dependent on myosin light
chain kinase, MLCK [7]. However, in several other studies, these
breaches were instead shown to be caused by the Rho A-ROCK
signaling pathway: in T84 and SK-CO15 human colonic epithelial
cells, contraction was dependent on the Rho A – ROCK pathway
activated by GEF-Hi [10] and, in rat brain endothelial cells,
depletion of extracellular Ca
2+ induced cell rounding in a RhoA-
dependent manner [14]. In the present study, we show ROCK to
be important for calcium depletion-induced contractility in L6
myotubes. By using this calcium-depletion model, we show that
stimulation of b-AR can inhibit cell contractility and detachment.
We also show that this signal is cAMP dependent but independent
of the classical downstream effectors PKA and Epac. Furthermore,
involvement of PKG, PI3K and PKC was ruled out. We show for
the first time that the mechanism is mediated by potassium
channels.
Results
Stimulation of b2-adrenergic receptors inhibits calcium
depletion-induced cell detachment
To verify that removal of extracellular Ca
2+ would lead to
changes in cellular shape as has been previously described [6,12]
we first employed CHO-K1 cells as a model system [15]. CHO
cells were subjected to calcium-free Phosphate buffered saline
(PBS) and after 20 minutes, all cells displayed sperical morphology
(Fig. 1A), confirming that CHO-K1 cells can be used in this assay.
CHO-K1 cells express very few or no b2-ARs under normal
conditions, and treatment with the b-AR agonist isoprenaline had
no effect on these cells (Fig. 1A). These observations were also
quantified by counting elongated versus spherical cells, and the
results in figure 1D show that following exposure to PBS, nearly
100% of the cells displayed a spherical morphology.
To investigate if b2-ARs could be involved in governing cellular
shape we used CHO cells stably transfected with human b2-AR
and tested these cells in our assay. After 20 minutes exposure to
calcium-free PBS, nearly all CHO b2-AR cells displayed spherical
morphology (Fig. 1B). We were surprised to find that with b-AR
agonist (isoprenaline) present in the calcium-free PBS the spherical
morphology was almost fully prevented and the cells displayed the
same (elongated) shape as control cells (Fig. 1E). These
observations were quantified by counting cells with spherical
versus elongated shape. Figure 1E shows that after exposure to
calcium-free PBS, the cells have close to 100% spherical shape but
when treated with isoprenaline, almost 100% of the cells kept their
elongated shape, despite the exposure to PBS. These results show
that the isoprenaline can prevent the rounding of the cells and that
the effect is meditated by the b2-AR. Confirming experiments
were done in CHO-cells transiently transfected with human b2-
AR, and here, too, isoprenaline prevented the rounding of the
calcium-free PBS treated cells (data not shown). We also noted that
upon prolonged exposure to calcium-free PBS (about 1 h) the cells
rounded and finally detached from the cell plate and that this
could be prevented with isoprenaline treatment. We also noted
that isoprenaline-treated cells eventually detached, but the effect of
isoprenaline lasted as long as 24 h (data not shown). This indicated
that activation of b2-AR could prevent both the spherical shape
and detachment. To better visualize the effect, the CHO b2-AR
cells were stained with FITC-phalloidin. Figure 1C confirms that
PBS treatment results in spherical morphology as well as
detachment of the cells, which is also indicated by the loss of
stress fibers. These changes were effectively prevented by
isoprenaline treatment.
Since CHO cells express negligible amount of b2-AR we wanted
to test a model system with endogenous b2-AR expression. L6
skeletal muscle cells express endogenous functional b2-ARs and
have been used for studies of b-adrenergic effects on muscle [5,16–
18]. In skeletal muscle, b-ARs are considered to be the most
important of the adrenoceptors with b2-AR as the predominant
subtype, and this is also true for the L6 rat skeletal muscle cells
[16,17]. Upon switching to low serum, L6 rat skeletal muscle cells
differentiate so that the myoblasts fuse to become large
multinucleated myotubes (Fig. 2A).
When exposed to calcium-free PBS or calcium chelators
BABTA, ethylene glycol tetraacetic acid (EGTA, not shown) or
EDTA (Fig. 2A and Fig. S1) in the media, the cells contracted and
detached from the surface of the dish. Calcium depletion has
previously been used in endothelial cells but we show for the first
time that this method can also be utilized in skeletal muscle cells.
Myotubes consist of a large number of fused myoblasts, which are
highly elongated in shape; under the described conditions, and
contraction of the myotubes leads to detachment from the growth
surface. After 10 min exposure to PBS, EDTA or BAPTA, the L6
myotubes contracted so that only 50% of the bottom of the well
was covered with cells and after 20 min this number had
decreased to around 25%. However, for cell that were pre-treated
with isoprenaline, and kept in PBS, EDTA or BAPTA with
continuous presence of this drug, the corresponding numbers was
100% after 10 min and 95% after 20 min.
Addition of b-AR agonist isoprenaline to all treatments
inhibited detachment of both myoblasts and myotubes (not shown,
Fig. 2 and Fig. S2). We have furthermore confirmed the same
effect in human primary skeletal muscle cells and C2C12 mouse
skeletal muscle cells (data not shown). Filamentous actin staining
with FITC-conjugated phalloidin was also performed in L6
myotubes and results show that PBS treatment leads to cell
detachment and isoprenaline treatment prevents this effect
(Fig. 2B).
Calcium depletion induces contractility leading to cell
detachment in L6 myotubes
Since addition of EDTA detached the cells from substrate but
did not separate L6 myotubes from each other, a combination of
EDTA and trypsin was used in order to obtain single cells. This
method made it possible to count the cells and thus quantify the
detachment. Upon exposure of L6 myotubes to trypsin?EDTA for
20 min, about 100% of cells had detached (Fig. 3B). Thus in the
following experiments, supernatant with detached cells were
collected after 20 min in trypsin?EDTA. Addition of isoprenaline
reduced detachment to about 10% of the control cells (Fig. 3A and
3B). When L6 mytoubes were exposed to trypsin alone, they
detached slower than by the combination of trypsin and EDTA
(Fig. 3C), and in contrast to the EDTA-effect, detachment caused
by trypsin was not inhibited by isoprenaline treatment. These
results imply that the b-adrenergic effect is independent of
adhesion processes involving, for example, integrins.
Isoprenaline treatment inhibited trypsin?EDTA induced con-
traction in both myoblast and myotubes, while the effect was much
more pronounced in the latter system (Fig. 3D and 3E).
Pretreatmant with isoprenaline for 30 min enhanced the effect,
but also acute addition of the drug togheter with trypsin?EDTA
gave a significant effect.
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22304Figure 1. b2-adrenoceptor-mediated inhibition of cell detachment in CHO cells. A) CHO-K1 cells were kept in culture media (CM) or
phosphate buffered saline (PBS) for 20 min with or without 30 min of pre-treatment with 1 mM isoprenaline (ISO). B) CHO cells stably transfected with
human b2-adrenoceptor in CM, PBS or PBS+ISO. C) FITC-Phalloidin-stained CHO b2-AR cells in CM, PBS or PBS+ISO. D) Morphology of CHO-K1 cells
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cells, we investigated the role of myosin, which is highly expressed
in these cells. It is well known that contraction can result in cell
detachment [6]. Contractility in cells is dependent on the motor-
protein myosin which operates via interaction with actin in the
cytoskeleton.
The non-muscle myosin II (NMII) blocker blebbistatin was used
in order to inhibit contractility without causing disassembly of the
actin cytoskeleton. Results show that blebbistatin inhibited the
EDTA/calcium depletion-induced cell detachment, confirming
the dependence of the contractile machinery (Fig. 3F).
To monitor the potential effect of the EDTA-treatment on
intracellular calcium levels, which could potentially affect
contractility, L6 myotubes were loaded with the green-fluorescent
calcium indicator Fluo-4. After 2 min in EDTA, when cells started
to contract, there was no significant change in intracellular
calcium levels (Fig. 4A). Isoprenaline treatment did not affect the
calcium levels, neither in cells kept in media nor during EDTA
exposure. The ionophore A23187, that is known to induce a rapid
increase in intracellular calcium, was used as positive control. This
treatment increased calcium levels significantly, verifying the
reliability of the system.
The contractility of NMII is regulated by phosphorylation of the
regulatory light chain, and the major kinase involved is myosin
light chain kinase (MLCK) a Ca
2+-calmodulin-dependent enzyme.
Since MLCK has been reported to be activated upon calcium
depletion [7], we investigated the involvement of this kinase with a
pharmacological blocker, ML-7. Cells detached in the presence of
the ML-7 (Fig. 4B) indicating that the regulation of NMII is not
dependent in this study.
There are also other kinases such as Rho-associated kinase
(ROCK) and citron kinase that can phosphorylate NMII. ROCK,
in particular, can also regulate NMII indirectly via inhibition of
MYPT [19], and depletion of extracellular Ca
2+ has been shown
to induce Rho A and ROCK activation in both colonic epithelial
and brain endothelial cells [10,14]. To test if ROCK is necessary
for contractility in our system we used the inhibitor Y-27632 to
block ROCK activity. Figure 4C shows that detachment of cells
induced by EDTA was blunted in response to Y-27632,
confirming the importance of ROCK for contractility. Another
approach is to study activation of Rho-ROCK by using
Lysophosphatidic acid (LPA), a small, ubiquitous glyceropho-
spholipid that has been used by other investigators to show the
involvement of ROCK-mediated contractility. LPA has five
receptor subtypes: LPA1–LPA5, which are encoded by genes
named LPAR1–LPAR5 in humans and Lpar1–Lpar5 in mice. All
five receptors are type I, rhodopsin-like GPCRs but differ in their
tissue distribution and downstream signaling pathways [20]. Most
mammalian cells exhibit varied responses to LPA (e.g. prolifera-
tion, cell migration or smooth muscle contraction) depending on
cell type [20]. LPA activates RhoA and is known to induce cell
morphology changes, increase endothelial permeability and inhibit
gap-junctional communication between adjacent cells [21]. Our
results showed that LPA inhibited the isoprenaline effect, resulting
Figure 2. Cell detachment induced by EDTA was inhibited in L6 cells by isoprenaline. A) Differentiated L6 myotubes were kept in culture
media (CM) or EDTA with or without 1 mM isoprenaline (ISO) for 20 min. The isoprenaline stimulated cells were pre-treated with this drug for 30 min
before EDTA exposure. B) FITC-Phalloidin-stained L6 myotubes in CM, EDTA or EDTA+ISO. Representative pictures from 3–6 independent
experiments.
doi:10.1371/journal.pone.0022304.g002
described by counting cells with elongated shape. The bars represents percentage of total cells. E) Morphology Quantification of CHO-b2 cells.
Histograms show percentage of total cells expressed as mean 6SEM of three independent experiments. *** p,0.001, one-way ANOVA.
doi:10.1371/journal.pone.0022304.g001
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This indicates that adrenergic signaling interacts with the Rho-
ROCK pathway. There was no significant difference between
LPA-treated and control cells after 20 min in trypsin?EDTA,
however we noted that at earlier time points that LPA-treatment
enhanced the speed of contraction. Taken together, our results
support previous findings that calcium depletion induces contrac-
tility via ROCK pathway.
b-adrenergic inhibition of contractility in a dose-
dependent manner
By using different concentrations of isoprenaline we show that
b-AR inhibition of contractility follows a Michaelis-Menten-
shaped dose-response curve (Fig. 5). Very low doses of isoprenaline
had an effect, indicating this to be a very sensitive system with a
pEC50–value at 9.760.4. The effect of b-adrenergic signaling can
have different sensitivity depending on which endpoint is studied.
Our previous results in L6 myotubes show that isoprenaline-
stimulated glucose uptake has a pEC50 at 8.99 [17], whereas the
endpoint of glycogen synthesis was less sensitive with a pEC50 at
7.46 [18].
b2-adrenergic receptor-mediated regulation of
contractility in L6 rat skeletal muscle cells is not
dependent on the classical b2-adrenergic signaling
pathway
To investigate the mechanism of b-adrenergic inhibition of cell
contractility and detachment we studied downstream signaling of
b-AR. As described above, activation of b-ARs leads to Gs-
mediated stimulation of adenylate cyclase (AC), elevated cAMP
levels and activation of PKA. The partial AC inhibitor ddA
showed a tendency to mitigate the cell contractility/detachment
inhibition caused by 1 mM isoprenaline. However, when used with
1 nM isoprenaline (a lower, but effective dose), ddA significantly
counteracted the isoprenaline-induced effects (Fig. 6A). This shows
that AC is involved and that probably only a small amount of
cAMP is enough to inhibit EDTA induced contractility.
To study the direct effects of cAMP, we used the cAMP
analogue 8-bromo-cAMP. Figure 6B shows that 8-bromo
mimicked the effect of isoprenaline almost completely, further
indicating cAMP dependence.
The traditional cAMP effector is PKA, but also Epac has also
been shown to be a dominant effector. Epac-activator 8-(4-
chlorphenylthio)-29-O-methyladenosine-39,59-cyclic monophos-
phate (8-CPT) was used but did not have any significant effect
on cell contractility and detachment (fig. 6 B) ruling out Epac as a
candidate.
PKA inhibitors 4-CM and rp-cAMP were used, but neither
could inhibit the isoprenaline effect (Fig. 6C), even at lower
isoprenaline concentrations (data not shown). Instead, 4-CM
mimicked the isoprenaline effect.
Another alternative signal would be activation of PKG, since
this kinase has been shown to act downstream of cAMP to control
contraction of smooth muscle cells [22]. We used the blocker KT
5823 to test PKG involvement, and subsequently ruled out PKG
as the isoprenaline effect was unaltered.KT5823 had in itself an
inhibitory effect on cell detachment.
Our previous studies of b-AR signaling in L6 myotubes show
that PI3K, or related kinases, act downstream of b2-AR, leading to
endpoints including glucose uptake and glycogen synthesis
[5,17,18]. PI3K has been implicated in several pathways
controlling key function of the cell, including motility, adhesion
and actin remodelling, and has also been shown to be important
for Ca
2+-dependent contraction in smooth muscle cells [23]. We
used the PI3K inhibitor LY294002; however, the results do not
show any involvement of PI3K (Fig. 6E). Consistent with these
findings, treatment with insulin could not inhibit calcium
depletion-induced contractility in L6 cells (Fig. 6E).
Another kinase involved in the regulation of cell adhesion and
contractility is PKC. In some systems, PKC enhances myosin
contractility via the PKC-potentiated myosin phosphatase inhib-
itor, CPI-17. In smooth muscles with high CPI expression, PKC-
activating agents can induce contraction; in species missing CPI,
the PKC activation instead reduces contraction [24]. Additionally,
in many non-muscle cells, PKC inhibits contraction via phos-
phorylation of myosin at ser1, ser2 or thr9 [19]. This is likely to be
the case for skeletal muscle models such as L6 since CPI-17 is only
expressed in smooth muscles cells [25]. To test this hypothesis, L6
myotubes were treated with PKC inhibitor Go ¨6983 but results
(Fig. 6 F) show that inhibition of PKC could not inhibit the
isoprenaline effect, suggesting that PKC is inessential in the
present pathway.
The b2-adrenergic receptor-mediated inhibition of
contractility is dependent on potassium-channels
b-adrenergic stimulation has been shown to affect potassium-
channels in some systems [4,26–28]and to investigate the possible
role of potassium channels in the current signal, we used the
general K
+-channel blocker, Tetraethylammonium (TEA). We
found that TEA could mitigate the 1 mM isoprenaline effect and
completely prevent the 1 nM isoprenaline effect (Fig. 7A).
We tested glibenclamide, an ATP-sensitive potassium channel
inhibitor, and charybdotoxin (CBX), an inhibitor of calcium-
activated potassium channels as well as some classes of voltage-
gated potassium channels. It has been previously shown that
glibenclamide can inhibit the b-adrenergic effect in smooth muscle
[26], and also in mesenteric arteries [28]). Yet, in rat pulmonary
arteries it did not affect isoprenaline-mediated relaxation [27], and
the same article reported that CBX had a partial effect on the
Figure 3. A quantitative cell detachment assay was used to investigate the involvement of myosin contractility in differentiated L6
cells. The amount of detached cells is expressed as % of basal where basal means cells that are not treated with any drugs before exposure to
trypsin?EDTA for 20 min. A) Cells were either kept in culture media (CM) during the whole experiment or expored to Trypsin?EDTA (T-E) for 20 min.
T-E+ISO indicated cells pre-treated for 30 min of 1 mM isoprenaline (ISO) before the 20 min exposure to T-E in the continuous presence of
isoprenaline (***). Histograms show percentage of unstimulated cells detached by T-EDTA expressed as mean 6SEM of four independent
experiments. ** p,0.01, *** p,0.001, one-way ANOVA versus control cells in T-EDTA. B) L6 myotubes kept in Trypsin?EDTA with (triangels) or without
(squares) isoprenline treatment. Aliquots of the detached cells were harvested and counted at the timepoints 10, 15, 20 and 25 min. C) L6 myoutbes
kept in trypsin alone with (triangles) or without (squares) isoprenaline treatment. Aliquots of the detached cells were harvested and counted at the
timepoints 10, 15, 20, 25 and 30 min. D) L6 myotubes were kept in Trypsin?EDTA for 20 min after 0 or 30 min pretreatment with isoprenaline. In both
C and D, point show % of cells detached after 20 min in Trypsin?EDTA. *** p,0.001 with one-way ANOVA for iso and acute iso versus control.
** p,0.01 for iso versus acute iso. E) L6 myoblasts were kept in Trypsin?EDTA for 3 min after 0 or 30 min pretreatment with isoprenaline.
*** p,0.001 with one-way ANOVA for iso and acute iso versus control. ** p,0.01 for iso versus acute iso. F) 30 min pre-treatment of 50 mM of the
myosin-inhibitor blebbistatin (blb) or 30 min of 1 mM ISO pre-treatment followed by 20 min of T-E exposure. *** p,0.001, one-way ANOVA versus
T-EDTA.
doi:10.1371/journal.pone.0022304.g003
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mide nor CBX could mimic or inhibit the isoprenaline effect,
thereby ruling out these classes of potassium channels as potential
candidates (Fig. 7B, C). Further investigations were done with the
potassium-channel agonist pinicidil, which has previously been
used to show that stimulation of the b-adrenergic pathway induced
K
+ channel activity in rabbit coronary smooth muscle cells [4].
Pinacidil inhibited contractility and detachment in response to
Figure 4. Characterization of the cell-detachment mechanism in L6 mytoubes. A) Intracellular levels of calcium were detected in L6
myotubes by the calcium-sensitive fluorescent dye Fluo-4. Control cells and cells pre-treated with 1 mM isoprenaline (ISO) were exposed to 1.6 mM
EDTA for 2–6 min. 10 mM of the ionophore A23187 (A23) was used as a positive control. N=4, *** p,0.001 one-way ANOVA for A23187 versus basal.
B) Detachment assay with cells pre-treated for 30 min with 1 mM isoprenaline (ISO) or 15 mM ML-7. Histograms show percentage of control cells
detached by T-EDTA expressed as mean 6SEM. N=3. *** p,0.001, one-way ANOVA versus ISO. C) 20 mM Y-27632 and D) 20 mg/ml LPA followed by
20 min exposure of Trypsin?EDTA. N=3–4, *** p,0.001 one-way ANOVA versus ISO or ISO+LPA.
doi:10.1371/journal.pone.0022304.g004
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(Fig. 7D), which corroborates our previous findings indicating that
potassium-channels are involved.
Discussion
b-adrenergic signaling exerts numerous effects in various tissues.
In the present study we have investigated the effect of b-adrenergic
signaling on cell detachment and contractility. Starting out with
CHO cells, which express negligible quantities of endogenous
adrenoreceptors, we utilized a calcium-depletion model to induce
cellular contractility. When treated with calcium-free PBS, CHO
cells round up to finally detach. In CHO cells with native receptor
expression, treatment with the b-AR agonist isoprenaline had no
effect on the morphological change seen after depletion of
extracellular calcium; in CHO cells transfected (either stably or
transiently) with the b2-AR, isoprenaline treatment prevented cell
rounding. Thus, isoprenaline treatment has a clear effect on cell
morphology and this effect is dependent on the b-AR. CHO cells
are easily transfectable and were therefore suitable for this
experiment.
For further experiments, however, we used a more physiolog-
ically appropriate model, the L6 skeletal muscle cells, which
express b2-AR endogenously. We have an interest in the b-AR
pathway. Specifically, the atypical signaling of b-AR to different
endpoints has previously been investigated by us and others by
using L6 skeletal muscle cells [17,18,29]. The present study has
never been performed in a skeletal muscle model system.
We developed a cell detachment assay to quantify the number
of cells that detach from the dish by using a combination of trypsin
and EDTA. The detachment of cells from the dish can depend
either on 1) direct inhibition of adhesion or 2) induced
contractility, and subsequent loss of adhesion.
Adhesion is mediated through interaction of integrins with
extracellular proteins. Trypsin treatment of cells effectively
removes these connections but we demonstrated that they are
unlikely to be involved in the b-adrenergic effect on cell
contractility and adhesion, because isoprenaline had no effect on
detachment induced by trypsin alone. Furthermore, the isopren-
aline effect was more pronounced in differentiated L6 myotubes
than in myoblasts. Myotubes contain more myosin and this goes in
line with our hypothesis that myosin is important in the current
process.
Although it is possible that isoprenaline could affect both
integrins and contractility, our results strongly support the idea
that the latter mechanism is the most important in our system.
The cell’s contractile machinery is driven by a dynamic
interaction between actin filament and myosin. There are about
20 classes of myosin of which class II is the largest and most well
known. To this class belong the different myosin isoforms
responsible for contraction of cardiac, skeletal and smooth
muscles, but also the non-muscle myosin, NMII, which is found
in all eukaryotic cells. Thus, muscle cells express both muscle
specific and non-muscle isoforms of myosin. Non-muscle myosin is
important for cell-cell and cell-matrix adhesion, migration and
cytokinesis [19]. Mechanical properties of a single cell such as
contractile forces are important for cell migration, neurite
extension, cytokinesis, muscle cell contraction, cell cycle progres-
sion, angiogenesis, and differentiation [30–36].
In the present study we establish that myosin-based contractility
is involved in contraction and detachment upon calcium depletion
since inhibition of myosin with blebbistatin yielded results similar
to those obtained with isoprenaline. L6 skeletal cells express a high
level of myosin, which makes our model system suitable for
studying contractility. We further investigated the contractile
machinery activated by calcium-depletion by ruing out the
possible role of MLCK, a kinase which regulates myosin by
phosphorylation. We proceeded to investigate another kinase,
ROCK, which also regulates myosin both directly, by phosphor-
ylation, and indirectly, by regulating a phosphatase, MLCP, that
in turn dephosphorylates myosin. Our results show that in our
system, calcium-depletion induced cell detachment via a ROCK-
dependent mechanism. Taken together our results suggest that it is
more likely that isoprenaline acts on the contractile machinery
than on the integrin system.
To study the pharmacological features of the isoprenaline effect
on contractility and cell detachment we performed a dose-response
study. These results revealed a highly sensitive system in which low
concentrations of the b-adrenergic agonist isoprenaline potently
effected contractility. In CHO cells, the calcium-depletion
response was weaker than in L6 cells, which could be explained
by the higher expression of myosin in L6. Additionally, several L6
cells fuse to become large myotubes which may accentuate and
accelerate the effect, due to leverage, and could be the reason for
the high sensitivity shown in the dose response curve.
We also investigated the classical downstream effectors of b-AR
in order to further understand the intracellular signal leading to
inhibition of contractility. By using the partial inhibitor of the
cAMP-producing enzyme adenylate cyclase (ddA) as well as a cell
permeable cAMP analogue (8-bromo-cAMP) we demonstrated
that cAMP is indeed involved in this system. Although, there are
several signaling cascades downstream of b-ARs, cAMP formation
is still considered to be one of the major events.
Several reports show that cAMP can affect cell morphology in
different model systems [37–39]. Increased cAMP-levels are also
shown to promote cell adhesion via Epac and Rap1, in Ovcar 3
cells and K562-cells [40,41]. Furthermore, cAMP can inhibit
contractile machinery in endothelial cells in during different
circumstances. For example, LPS induces cell contraction [42] and
thrombin-induced endothelial hyperpermeability [43,44].
Figure 5. Isoprenaline inhibits contractility in a dose-depen-
dent manner. L6 myotubes pre-treated with different concentrations
of isoprenaline for 30 min followed by 20 min exposure to Trypsi-
n?EDTA. Dose response curve show percentage of T-EDTA expressed as
mean 6SEM of six independent experiments.
doi:10.1371/journal.pone.0022304.g005
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PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22304In this study, we have found a b-adrenergic pathway that is
distinct from the adrenergic glucose uptake pathway described in
previous papers [5,17]. By using pharmacological inhibitors we
demonstrate that neither PKA, Epac, PKG, PI3K nor PKC are
involved. The isoprenaline effect was not reduced by the inhibitors
although two of them (4-CM and KT5823) could partly mimic the
isoprenaline effect by themselves. This would either be due to that
PKA and PKG are positively regulating contraction or that
inhibitors exert unspecific effects leading to inhibition of
contraction. The main conclusions from these experiments are
that the b-adrenergic effect studied in this paper does not follow
the classical b-AR signaling pathway.
b-adrenergic inhibition of contraction is a well-known phenom-
enon in smooth muscle. Smooth muscle myosin and non-muscle
myosin have similar regulation through phosphorylation of the
myosin regulatory light chain. This is distinct from cardiac and
skeletal muscle myosin which is regulated by the troponin/
tropomyosin complex. Thus we find it likely that b-adrenergic
stimuli could affect both smooth muscle myosin and non-muscle
myosin and in similar manner.
There are different proposed models for the b-adrenergic action
in smooth muscles and the exact mechanism seems to vary
between species [45]. In porcine and bovine airway smooth
muscle, isoprenaline is shown to act both by modulation of Ca
2+-
flux via SERCA as well as by increasing activity of the myosin light
chain phosphatase (MLCP) [46]. Another suggested mechanism is
opening of potassium-channels (reviewed in [47]). In smooth
muscle systems is shown that b-adrenergic stimulation induces
membrane hyperpolarization via opening of K
+-channels
[4,27,28].
Recent studies have revealed that b-AR can activate various
classes of potassium channels [4,26–28]. Thus, we continued
investigating the potential involvement of such channels in our
system. Potassium channels have different numbers of transmem-
brane domain (TM) depending on the class but all of them have a
tetrameric structure which is arranged in four subunits around a
central ion conducting pore (P), forming both homotetramers and
heterotetramers. There are four major classes of potassium
channels: calcium-activated potassium channels, which respond
to calcium or other signaling molecules; inwardly rectifying
potassium channels, which conduct potassium ions more easily
into the cell; tandem pore domain potassium channels, which are
constitutively open or more active and contribute to the resting
potential, and; voltage-gated potassium channels, which function
to regulate membrane potential by repolarization of the action
potential in nerve cells.
b-ARs have been shown to activate different potassium channels
in different tissues. There is evidence that cAMP can directly
induce the activation of potassium channels [48]. We therefore
tested whether b-AR signaling via cAMP could act directly on
potassium-channels and prevent cell detachment and contractility
in response to calcium depletion. By using different pharmaco-
logical approaches such as inhibition of potassium channel activity
with TEA or activate with pinacidil we showed that the
isoprenaline effect is mainly dependent on potassium channels.
In narrowing down the candidates to a class of potassium
channels, we ruled out the involvement of ATP-sensitive
potassium channels and calcium-activated potassium channels by
showing that the inhibitors glibenclamide and charybdotoxin did
not reduce the effect of isoprenaline on cell detachment and
contractility. Further elucidation of the involved potassium
channel through electrophysiology and molecular remains more
than a trivial undertaking, as circa 80 potassium channels have
been identified. Furthermore, the pharmacological profile is
complicated and it is not current possible to only inhibit a specific
class of potassium channel.
One possible effect on calcium depletion could be changes in
the intracellular calcium levels. Here we show that in the presence
of EDTA, there is a tendency towards decreased intracellular
calcium in the L6 myotubes. This effect was however not changed
by b-adrenergic stimulation. Thus, even if EDTA might affect
intracellular calcium levels, this is not the effect that b-adrenergic
signaling interferes with. Instead it is more likely to interfere with
the depolarization caused by calcium removal. Depolarization can
be counteracted by opening of potassium channels, and this event
is, according to our present findings, promoted by cAMP that is
produced downstream of the b2-receptor.
Sympathetic signaling is a part of the autonomic nervous system
and regulates almost all organs in the body, leading to e.g.
accelerating heart rate, releasing triglycerides from fat and glucose
from liver, increasing blood flow and glucose uptake in skeletal
muscle, dilating pupils and airways, and reducing gut movements.
It is possible that regulation of non-muscle myosin is involved in
several of these processes both in normal physiology and
pathophysiology. For example, b-adrenergic inhibitor of contrac-
tility is a known phenomenon for smooth muscle cells, but we
show here that it is likely that b-adrenergic signaling can regulate
the myosin-machinery in several tissues. Myosin-dependent
contraction is involved in a multitude of physiological processes
such as cell shape, adhesion and tissue architecture. Enhanced
myosin-dependent contraction is also associated with several
diseases such as Crohn’s disease, NSAID-associated enteritis,
diarrheal syndromes as well as different evens during cancer such
as invasion, metastasis and contraction of endothelial cells allowing
intravasation of tumor cells [49,50]. The calcium depletion model
that is used in the current paper to activate myosin has previously
been used to mimic the state of increased myosin-contraction that
occurs during those diseases [7,14]. Interestingly, in the current
paper we show that the kinase ROCK is activated during calcium-
depletion, and this kinase is shown to plays an essential part in
tumor cell invasion and has been suggested as a potential
therapeutic target for the prevention of cancer invasion and
metastasis [51,52,53]. Thus, further understanding of how b-
adrenergic signaling does inhibit myosin contraction could
potential lead to the finding of new drug targets for several
diseases.
In conclusion, we present here the novel finding that b-
adrenergic signaling can greatly affect cell morphology, especially
Figure 6. Isoprenaline inhibits contractility via cAMP in differentiated L6 cells. A) L6 myotubes were pre-treated with 50 mM ddA for
30 min before stimulation with 1 mM or 1 nM isoprenaline (ISO), 30 min following 20 min Trypsin?EDTA exposure. Histograms show percentage of
control cells detached by T-EDTA expressed as mean 6SEM of three independent experiments. *** p,0.001, one-way ANOVA versus ISO. B) L6 cells
were stimulated with 1 mM ISO or 1 mM of the cAMP-analogues 8-bromoadenosine-39,59-cyclic monophosphate, 8-bromo (30 min),
N
6-benzoyladenosine-39,59-cyclic monophosphate, or 59- cyclic monophosphate, 8-CPT (30 min) followed by treatment of Trypsin?EDTA. N=3. C)
1 mM ISO, 20 mM rp-cAMP (30 min before addition of iso) and 10 mM 4-CM (30 min before addition of iso) N=3 D) 1 mM ISO and 10 mM KT 5823
(30 min before addition of iso) E) 1 mM ISO, pre-treatment with the LY294002 (LY, 30 min before addition of iso) or 1 mM insulin (INS, 30 min) N=2–3 F)
1 mM ISO, pre-treatment with 5 mMG o ¨9683 for 5 min before addition of isoprenaline followed by 20 min exposure of Trypsin?EDTA, N=2–3.
doi:10.1371/journal.pone.0022304.g006
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adrenergic or cAMP signaling. We show that these morphological
changes, induced by b-adrenergic signaling, are extremely
sensitive and occur via myosin-dependent contractility. The
mechanism for the inhibition of contractility by b-adrenergic
agonist isoprenaline is dependent on potassium channels.
Figure 7. Potassium channels inhibit calcium depletion-induced contractility. A) L6 myotubes were pre-treated with 100 mM
tetraethylammonium (TEA) for 10 min prior to 1 mM isoprenaline (ISO). Histograms show percentage of T-EDTA expressed as mean 6SEM. N=3–4.
*** p,0.001, student t-test versus ISO. B) 10 min exposure of 100 mM glibenclamide (GLB), N=3 C) 10
27 M charybdotoxin (CBX) treated for 10 min
N=3 D) 100 mM pinacidil (PIN) for 10 min followed by Trypsin?EDTA exposure for 20 min. N=3–4, *** p,0.001 versus Trypsin?EDTA.
doi:10.1371/journal.pone.0022304.g007
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Cell culture
CHO-K1 and CHO-b2 were obtained as a gift from Roger
Summers, Monash University and grown in DMEM/Hams-F12
medium supplemented with 10% FBS, 4 mM L-glutamine,
4500 mg/L D-glucose and maintained in water jacketed incuba-
tors at 37uC and 5% CO2.
L6 cells were purchased from American Type Culture
Collection and grown in DMEM supplemented with 10% FBS,
2 mM L-Glutamine, 50 U/ml penicillin and 50 mg/ml strepto-
mycin in a 37uC incubator with 8% CO2. To induce
differentiation, serum levels were decreased to 2% for 7–8 days.
Fluorescent staining
CHO-b2 cells were seeded out on cover slips the day before the
experiment while L6 cells were grown on cover slips until reaching
confluence followed by differentiation for 7 days. On the day of
the experiment, cells were washed in PBS and immediately fixed
(control) or kept in PBS for additionally 20 min (CHO cells) or
3 min (L6 mytoubes) in the presence or absence of 1 mM
isoprenaline before fixation with 4% formaldehyde for 20 min at
room temperature. Cells were permeabilized with 0.25% Triton-
X100 for 10 min and FITC-conjugated phalloidin (Sigma-
Aldrich; St. Louis, MO) was used to stain filamentous actin. The
fluorescence was detected in a Leica DMLB epifluorescence
microscope, equipped with a DC350F camera and using IM500
software (Leica Microsystems AB; Kista, Sweden).
Adhesion assay CHO-cells
Cells were seeded out in 6-well plates and left overnight to
adhere. Medium was changed to serum-free medium for 3 h. Cells
were washed in PBS and kept in PBS or EDTANtrypsin as
indicated.
Adhesion assay L6 myotubes
On day 7 or 8 of differentiation, cells were incubated with
inhibitors for the time indicated for each experiment, before
treatment with isoprenaline (1 mM). After 30 min isoprenaline
treatment, media was removed, cells washed once and then kept in
trypsinNEDTA (2.5 g porcine trypsin, 0.2 g EDTAN4Na per liter
HBSS), in continues presence of drugs and inhibitors, for 20 min
(myotubes) or 3 min (myoblasts) at room temperature. At this
timepoint, the plate was swirled gently in order to mix the
detached cells, and supernatant was collected and the detached
cells were counted in a single use Bu ¨rker chamber (ISL Immune
Systems). Cells were pretreated with different pharmacological
agents at this time at concentrations indicated in the text. All
reagents were purchased form Sigma with exception of 4-cyano-3-
methylisoquinoline (4-CM), which was purchased from Calbio-
chem, LY 294002 is from Alexis biochemicals and N6-benzoyl-
cAMP and 8-pCPT-2-O-Me-cAMP from Biolog Life Science
Institute. Detached cells are expressed as % of control.
Measurement of intracellular calcium
Intracellular calcium-levels were detected by the fluorescent
calcium-specfic dye Fluo-4 AM (Invitrogen). Differentiated L6
myotubes were loaded with dye according to the manufactures
instructions and fluorescence was detected by in a Leica DMLB
epifluorescence microscope, equipped with a DC350F camera and
using IM500 software (Leica Microsystems AB; Kista, Sweden).
Cells were treated with either the calcium ionophore A23187
(Sigma) or expose to EDTA in the absence or presence of
isoprenaline. Flouresence intensity was quantified by the software
MacBiophotonics ImageJ (McMaster Biophotonics Facility,
McMaster University, Canada).
Data Analysis
All data are expressed as mean 6 s.e.mean of n. Analysis of
difference was carried out with one-way ANOVA or Student t-test
(Graph-pad PRISM). A value of p,0.05 was considered statistical
significant.
Supporting Information
Figure S1 EDTA-exposure induces contractility in L6 myo-
tubes. On day seven of differentiation, culture media was removed
and L6 myotubes were exposed to EDTA for 20 min. Pictures
were taken every 30 second.
(MOV)
Figure S2 Isoprenaline inhibits EDTA-induced contractility in
L6 cells. On day seven of differentiation, cells were pre-treated
with 1 mM isoprenaline for 30 min before exposure to EDTA for
20 min, in the continuous presence of isoprenaline. Pictures were
taken every 30 second.
(MOV)
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